C12N 2501/603
Oct-3/4
C12N2501/603 (Oct-3/4) appears on 407 US grants and 753 published applications in this corpus.
Search patents in C12N- Granted patents
- 407
- Published applications
- 753
- Assignees
- 291
- Inventors
- 1,074
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 2 |
| 2009 | 0 | 10 |
| 2010 | 2 | 31 |
| 2011 | 4 | 47 |
| 2012 | 7 | 48 |
| 2013 | 14 | 57 |
| 2014 | 19 | 41 |
| 2015 | 31 | 39 |
| 2016 | 34 | 48 |
| 2017 | 31 | 52 |
| 2018 | 35 | 48 |
| 2019 | 36 | 49 |
| 2020 | 27 | 39 |
| 2021 | 39 | 62 |
| 2022 | 27 | 50 |
| 2023 | 19 | 37 |
| 2024 | 33 | 40 |
| 2025 | 27 | 37 |
| 2026 | 22 | 15 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Composition for enhancing reprogramming efficiency from somatic cell to induced pluripotent stem cell, comprising mTOR activator, and method for enhancing reprogramming efficiency by using same6 Oct 2026US 12,753,394 B2Korea University Research and Business Foundation
- Immune cells derived from induced pluripotent stem cell14 Jul 2026US 12,680,075 B2Children's Medical Center Corporation
- And efficient method for reprogramming blood to induced pluripotent stem cells14 Jul 2026US 12,680,082 B2Cedars-Sinai Medical Center
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy16 Jun 2026US 12,655,389 B2Iovance Biotherapeutics, Inc.
- RNA preparations comprising purified modified RNA for reprogramming cells16 Jun 2026US 12,655,395 B2
- Oct3/4 protein variants, and method for producing induced pluripotent stem cells1 Oct 2026US 2026/0297535 A1Riken
- Rna preparations comprising purified modified rna for reprogramming cells1 Oct 2026US 2026/0297538 A1The Trustees of the University of Pennsylvania
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272985 A1Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272986 A1Iovance Biotherapeutics, Inc.
- System and method for capillary blood stem cell reprogramming using upper-arm blood collection devices for patient-specific disease modeling10 Sep 2026US 2026/0265698 A1TimepointDx
Most cited
By later US patents
- Nuclear reprogramming factor151US 8,048,999 B2Kyoto University · 2011
- Vectors and methods for the efficient generation of integration/transgene-free induced pluripotent stem cells from peripheral blood cells126US 9,850,499 B2Loma Linda University · 2017
- Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells125US 8,058,065 B2Kyoto University · 2011
- Compositions and methods for reprogramming eukaryotic cells103US 8,808,982 B2Cellscript, LLC · 2014
- Methods for reprogramming somatic cells96US 7,682,828 B2Whitehead Institute for Biomedical Research · 2010